Duodenal mucosal interventions in the era of glucagon-like peptide-1 receptor agonists

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic polypeptide/GLP-1RAs have transformed the treatment of type 2 diabetes and obesity. However, adverse effects, cost, access, treatment burden, and weight regain after drug withdrawal highlight the need to investigate durable complementary strategies. Duodenal mucosal resurfacing (DMR) modifies maladaptive duodenal signaling via controlled mucosal injury and regeneration. In the sham-controlled REVITA-2 trial, hydrothermal DMR did not significantly improve glycated hemoglobin or liver fat in the overall population, although prespecified European analyses suggested metabolic benefit. Small open-label studies combining hydrothermal DMR or recellularization using electroporation therapy with GLP-1RA treatment reported insulin discontinuation in selected patients, but the procedural contribution could not be separated from pharmacotherapy and lifestyle interventions. Thus, it remains unproven whether duodenal intervention can maintain metabolic benefits after GLP-1RA withdrawal. Emerging systems differ substantially in energy source, tissue target, procedural workflow, and safety profile. A delayed perforation after laser ablation underscores the integral role of dosimetry, catheter stability, insufflation, and surveillance in safety. At present, duodenal mucosal interventions should be confined to clinical trials. Randomized sham-controlled studies with standardized background therapy, clinically relevant safety outcomes, and long-term follow-up are necessary to define their complementary role in the incretin era.

Authors

Institutions

Publication Details

Journal
Journal of Innovative Medical Technology
Published
2026-11-18
DOI
https://doi.org/10.61940/jimt.260009
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Duodenal mucosal interventions in the era of glucagon-like peptide-1 receptor agonists

Su Jin Kim
1 links
Journal of Innovative Medical Technology
Diabetes Treatment and Management
article

Duodenal mucosal interventions in the era of glucagon-like peptide-1 receptor agonists

Su Jin Kim
article en

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic polypeptide/GLP-1RAs have transformed the treatment of type 2 diabetes and obesity. However, adverse effects, cost, access, treatment burden, and weight regain after drug withdrawal highlight the need to investigate durable complementary strategies. Duodenal mucosal resurfacing (DMR) modifies maladaptive duodenal signaling via controlled mucosal injury and regeneration. In the sham-controlled REVITA-2 trial, hydrothermal DMR did not significantly improve glycated hemoglobin or liver fat in the overall population, although prespecified European analyses suggested metabolic benefit. Small open-label studies combining hydrothermal DMR or recellularization using electroporation therapy with GLP-1RA treatment reported insulin discontinuation in selected patients, but the procedural contribution could not be separated from pharmacotherapy and lifestyle interventions. Thus, it remains unproven whether duodenal intervention can maintain metabolic benefits after GLP-1RA withdrawal. Emerging systems differ substantially in energy source, tissue target, procedural workflow, and safety profile. A delayed perforation after laser ablation underscores the integral role of dosimetry, catheter stability, insufflation, and surveillance in safety. At present, duodenal mucosal interventions should be confined to clinical trials. Randomized sham-controlled studies with standardized background therapy, clinically relevant safety outcomes, and long-term follow-up are necessary to define their complementary role in the incretin era.

Journal of Innovative Medical TechnologyVol. 4(2)
Pusan National University Yangsan Hospital (KR)
Good health and well-being
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon